DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Caffo O, Bria E, Giorgi UD. et al.
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: final analysis from a multicenter Italian study.
ASCO J Clin Oncol 2017;
35: 5030
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.